MarketCap
Facebook
X
Telegram
Cyclacel Pharmaceuticals Balance Sheet 2025-1997 | CYCCP
Brief overview of Cyclacel Pharmaceuticals's balance sheet structure
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
Assets fell from $42.6 million to $8.2 million. This may reflect either deliberate optimization or a reduction in business scale.
Asset growth of -80.8% was close to the -74.8% change in liabilities, leaving the funding profile broadly stable.
Internal capital represents 83.6% of the balance sheet, previously 87.5%. This is a strong capital position.
Negative net debt of -$3.5 million means cash holdings are larger than debt obligations.
The cash share moved from 85.8% to 42.8%. A higher figure generally provides more room in an adverse scenario.
The balance sheet carries negative retained earnings of -$454.4 million. The figure may result from accumulated losses or an active capital return policy.
Conclusion
Cyclacel Pharmaceuticals's balance sheet sends more positive than negative signals, but liabilities should not begin outpacing the capital base.
Annual Balance Sheet Cyclacel Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-3.5 M | - | -3.34 M | -18.2 M | -36.5 M | -32.3 M | -10.7 M | -17.4 M | -23.9 M | -16.5 M | -20.4 M | -24.2 M | -31.1 M | -16.4 M | -24.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt |
2 K | - | 37 K | 106 K | 30 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 1.06 M | 1.19 M | 100 K | 124 K | 130 K | 176 K | 206 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
1.33 M | 6.27 M | 8.16 M | 7.51 M | 5.29 M | 2.49 M | 2.42 M | 4.45 M | 4.11 M | 5.26 M | 5.75 M | 7.49 M | 7.5 M | 9.34 M | 6.5 M | 6.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
1.34 M | 6.27 M | 8.2 M | 7.62 M | 5.32 M | 3.54 M | 3.61 M | 4.55 M | 4.24 M | 5.39 M | 5.93 M | 7.7 M | 7.5 M | 9.34 M | 6.5 M | 6.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-454 M | -439 M | -428 M | -406 M | -385 M | -366 M | -358 M | -350 M | -343 M | -335 M | -323 M | -309 M | -289 M | -270 M | -257 M | -242 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
8.18 M | 4.09 M | 8.8 M | 28 M | 42.6 M | 36.8 M | 15.3 M | 19.8 M | 26 M | 19.7 M | 24.8 M | 29.4 M | 35.5 M | 19.4 M | 26 M | 31.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
3.5 M | 3.14 M | 3.38 M | 18.3 M | 36.6 M | 33.4 M | 11.9 M | 17.5 M | 23.9 M | 16.5 M | 20.4 M | 24.2 M | 31.1 M | 16.4 M | 24.4 M | 29.5 M | 11.5 M | 24.2 M | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
6.84 M | -2.17 M | 607 K | 20.4 M | 37.3 M | 33.3 M | 11.7 M | 15.3 M | 21.8 M | 14.3 M | 18.8 M | 21.7 M | 28 M | 10 M | 19.5 M | 24.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
6.84 M | -2.17 M | 607 K | 15.9 M | 37.3 M | 33.3 M | 11.7 M | 15.3 M | 21.8 M | 14.3 M | 18.8 M | 21.7 M | 28 M | 10 M | 19.5 M | 24.9 M | 5.87 M | 20.6 M | 58 M | 53.9 M | 4.12 M | 24 M | 37.6 M | -15.1 M | -2.59 M | 7.98 M | -1.54 M | 2.01 M | -293 K |
All numbers in USD currency
Quarterly Balance Sheet Cyclacel Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
2 K | 5 K | 10 K | 9 K | - | - | 5 K | 21 K | 37 K | 52 K | 66 K | 80 K | 106 K | 107 K | 113 K | 15 K | 30 K | 44 K | - | 996 K | 1.06 M | 1.06 M | 1.06 M | 1.06 M | 1.19 M | 1.19 M | 1.19 M | 1.19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
804 K | 1.06 M | 770 K | 672 K | 6.27 M | 6.35 M | 7.19 M | 8.37 M | 8.2 M | 8.2 M | 6.81 M | 7.42 M | 7.5 M | 4.46 M | 5.14 M | 6.22 M | 5.32 M | 3.64 M | 3.12 M | 3.77 M | 3.54 M | 3.54 M | 3.54 M | 3.54 M | 3.61 M | 3.61 M | 3.61 M | 3.61 M | 4.55 M | 4.55 M | 4.55 M | 4.55 M | 4.24 M | 4.24 M | 4.24 M | 4.24 M | 5.39 M | 5.39 M | 5.39 M | 5.39 M | 5.93 M | 5.93 M | 5.93 M | 5.93 M | 7.7 M | 7.7 M | 7.7 M | 7.7 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 9.34 M | 9.34 M | 9.34 M | 9.34 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M |
Retained Earnings |
-455 M | -444 M | -442 M | -440 M | -439 M | -436 M | -434 M | -431 M | -428 M | -423 M | -417 M | -412 M | -406 M | -399 M | -394 M | -389 M | -385 M | -380 M | -375 M | -370 M | -366 M | -366 M | -366 M | -366 M | -358 M | -358 M | -358 M | -358 M | -350 M | -350 M | -350 M | -350 M | -343 M | -343 M | -343 M | -343 M | -335 M | -335 M | -335 M | -335 M | -323 M | -323 M | -323 M | -323 M | -309 M | -309 M | -309 M | -309 M | -289 M | -289 M | -289 M | -289 M | -270 M | -270 M | -270 M | -270 M | -257 M | -257 M | -257 M | -257 M |
Total Assets |
7.56 M | 8.16 M | 4.4 M | 3.73 M | 4.09 M | 5.38 M | 8.19 M | 6.16 M | 8.8 M | 12.5 M | 16.4 M | 22.1 M | 27.5 M | 31 M | 35.3 M | 39.6 M | 42.6 M | 45 M | 46.3 M | 51.8 M | 36.8 M | 36.8 M | 36.8 M | 36.8 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 19.8 M | 19.8 M | 19.8 M | 19.8 M | 26 M | 26 M | 26 M | 26 M | 19.7 M | 19.7 M | 19.7 M | 19.7 M | 24.8 M | 24.8 M | 24.8 M | 24.8 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 26 M | 26 M | 26 M | 26 M |
Cash and Cash Equivalents |
3.34 M | 3.84 M | 4.28 M | 3.45 M | 3.14 M | 2.98 M | 6 M | 2.8 M | 3.38 M | 5.94 M | 10.2 M | 11.4 M | 18.3 M | 23.7 M | 29.1 M | 29.6 M | 36.6 M | 40.2 M | 43.6 M | 47.8 M | 33.4 M | 33.4 M | 33.4 M | 33.4 M | 11.9 M | 11.9 M | 11.9 M | 11.9 M | 17.5 M | 17.5 M | 17.5 M | 17.5 M | 23.9 M | 23.9 M | 23.9 M | 23.9 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 24.2 M | 24.2 M | 24.2 M | 24.2 M | 31.1 M | 31.1 M | 31.1 M | 31.1 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 24.4 M | 24.4 M | 24.4 M | 24.4 M |
Book Value |
6.76 M | 7.1 M | 3.63 M | 3.06 M | -2.17 M | -970 K | 999 K | -2.21 M | 607 K | 4.3 M | 9.63 M | 14.6 M | 20 M | 26.6 M | 30.2 M | 33.4 M | 37.3 M | 41.4 M | 43.2 M | 48 M | 33.3 M | 33.3 M | 33.3 M | 33.3 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 21.8 M | 21.8 M | 21.8 M | 21.8 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 21.7 M | 21.7 M | 21.7 M | 21.7 M | 28 M | 28 M | 28 M | 28 M | 10 M | 10 M | 10 M | 10 M | 19.5 M | 19.5 M | 19.5 M | 19.5 M |
Total Shareholders Equity |
6.76 M | 7.1 M | 3.63 M | 3.06 M | -2.17 M | -970 K | 999 K | -2.21 M | 607 K | 4.3 M | 5.14 M | 10.1 M | 15.5 M | 22.1 M | 30.2 M | 33.4 M | 37.3 M | 41.4 M | 43.2 M | 48 M | 33.3 M | 33.3 M | 33.3 M | 33.3 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 21.8 M | 21.8 M | 21.8 M | 21.8 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 21.7 M | 21.7 M | 21.7 M | 21.7 M | 28 M | 28 M | 28 M | 28 M | 10 M | 10 M | 10 M | 10 M | 19.5 M | 19.5 M | 19.5 M | 19.5 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Cyclacel Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
